MMMalaisamy Muniyandi

Malaisamy Muniyandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Malaisamy Muniyandi has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Karikalan Nagarajan

    ICMR-National Institute for Research in Tuberculosis

    8 shared publications
  • Kavitha Rajsekar

    Government of India

    6 shared publications
  • Karikalan Nagarajan

    Indian Council of Medical Research- National Institute for Research in Tuberculosis Department of Social & Behavioural Research Chen nai 600031

    5 shared publications
  • Karthick Chelvanayagam

    Department of Health Economics, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India

    5 shared publications
  • Chandrasekaran Padmapriyadarsini

    Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India

    4 shared publications
  • Sahil Abdul Salam

    ICMR-National Institute for Research in Tuberculosis

    4 shared publications

Latest Publications

  • Open Access

    Cost comparison of UniAMP with Truenat for tuberculosis detection in India

    by Malaisamy Muniyandi, Sahil Abdul Salam, Venkateshprabhu Janagaraj, Priya Rajendran, Silla Varghese Thomas, Kavitha Rajsekar, Karikalan Nagarajan

    Delayed diagnosis of tuberculosis (TB) contributes to increased transmission, morbidity and mortality. Traditional TB diagnostic tools like smear microscopy and X-ray have limited sensitivity espec...


  • Open Access

    Tuberculosis Knowledge, Attitude, and Practice (TB-KAP) among the volunteers: Findings from community-based intervention training outcome in Tribal Hard-to-Reach Areas in Manipur

    by Karikalan Nagarajan, Stephen Arangba, Basilea Watson, Muniyandi Malaisamy, Linette Muanching, Suchita Singh, Sanjay Kumar Mattoo, Vijaya Elangbam, W. Shashi Singh, Senthil Sellappan, et al.

    Background: Involving community volunteers in the tuberculosis (TB) program is widely acknowledged and considered a key element of the community engagement strategy in the TB program of India, especially in predominantly tribal North Eastern districts. Inadequate TB knowledge, attitudes and Practices (KAPs) about health and related risk factors could be a key barrier to using community volunteers or lay persons in health program. Methods: We trained 708 volunteers from student and women organisation (SAWOs) in 189 villages, Senapati District, Manipur between February 2023 and August 2025. A training on identifying TB symptomatics, sputum collections, transportations, patient support and follow-up during their treatment, counselling were provided. A TB-KAP pre and post data were collected in REDCap software and analysed using Stata. To assess the impact of the training on participants’ KAP regarding TB, both descriptive and inferential statistical methods were used. Statistical significance was determined at p-value t (353)=−3.58, p = 0.0004), with a 95% confidence interval of [−1.35, −0.39]. Significant positive changes were seen in the anticipated health-seeking intentions of the volunteers in terms of seeking care for symptoms within 1–2 weeks ( p = 0.0009). Conclusion: Our study demonstrated that focused and culturally appropriate short term training can produce significant immediate gains in TB knowledge, with modest improvements in attitudes and reported health-seeking intentions, even in the remotest tribal areas among community volunteers.

  • Open Access

    An overview of mobile health applications (mHealth apps) supporting Tuberculosis elimination efforts

    by Karikalan Nagarajan, Nickson Rajamani, Shelshia Muniappan, Aswin Vickirananth Jeyachithra, Yasaswany Santhoshkumar, Archana Verma, Arangba Stephen, Malaisamy Muniyandi

    Background: The rapid advancement of mobile health applications (mHealth Apps) is increasingly realised for their transformative potential in strengthening healthcare systems, patient centred approaches and improving TB elimination efforts. Objective: To provide a landscape overview of mHealth Apps which are operational to support the TB elimination efforts with reference to specific functionalities that support either persons with TB or healthcare providers. Methods: We conducted a systematic search of the Google Play and Apple App Store to collect mHealth Apps developed for TB care and management. Information on features of the mHealth Apps were collected based on the WHO Classification of Digital Interventions, Services and Applications in Health. App purpose, functionality and target audience were synthesised from App descriptions and classified based on the framework. The mHealth Apps were summarized in frequency and percentages. Results: Of 196 Apps identified, based on inclusion and exclusion criteria, 48 were included for the final analysis. When categorised by the intended users, 22 (46%) were health worker oriented, 10 (21%) were beneficiary focused and 16 (33%) were intended for a mixed audience. On demand information for beneficiary and personal health tracking feature was available in 18(38%) and 14 (29%) of the Apps, respectively. Telemedicine, laboratory management features were available in less than one-fifth of Apps. Features for health worker decision support, referral coordination and data interoperability were very low. There were no features with respect to human resource and supply chain and health financing. Conclusion: There is a need for developing more community centric and frontline worker oriented Apps through participatory co-designing involving people affected by TB, community organisations and frontline health workers for guiding the development in future.

  • Open Access

    Understanding participation of persons with disabilities in clinical trial research in India—a retrospective analysis of inclusive language of protocols

    by Karikalan Nagarajan, Malaisamy Muniyandi, Aswin Vickirananth Jeyachithra, Shelshia Muniappan, Nickson Rajamani, Pearl Maria Dsouza, Yasaswany Santhoshkumar, Ananda Kumar Balasubramanian, Bhaskara Chary Kothoju, Priscilla Rebecca, et al.

    The under-representation of vulnerable groups in clinical trials, including persons with disabilities, could affect the applicability of trial findings to

  • Open Access

    Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB

    by Malaisamy Muniyandi, Karikalan Nagarajan, Karthick Chelvanayagam, Kavitha Rajsekar, Kirti Tyagi, Chandrasekaran Padmapriyadarsini

    Background & objectives: Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquiline, pretomanid, linezolid (BPaL) and BPaL with moxifloxacin (BPaLM). We conducted an economic evaluation to assess whether the introduction of BPaL/BPaLM regimen under National Tuberculosis Elimination Programme (NTEP) for the treatment of multi-drug resistant (MDR)/RR-TB is a cost-effective strategy. The idea was to estimate the incremental cost incurred from BPaL/BPaLM regimen in comparison with the current mix of standard of care (SoC) regimen. Methods: We used an economic model comprising a Markov analysis. The study estimated the incremental costs, life years gained and quality adjusted life years (QALYs) gained by the introduction of BPaL/BPaLM regimen for MDR/RR-TB patients. A scenario analysis for different proportions of shorter and longer SoC regimen compared with BPaL/BPaLM was also done. Cost threshold analysis was done to assess the ideal cost at which the drug BPaL/BPaLM turns into cost-saving. Budget impact analysis was conducted to assess the financial implications of adopting BPaL/BPaLM compared to mix SoC, supporting informed decision-making alongside cost-effectiveness analysis for one year. Results: The base case analysis showed the total discounted costs by health system perspective for the BPaL, BPaLM and the current mixed SoC were INR 2515, INR 2644 and INR 2630 million, respectively. The ICER for BPaL was INR -379 which indicates that we have to spend INR 379 less per patient for BPaL than the mixed SoC to gain one QALY. The ICER for BPaLM was INR 37 which indicates that we have to spend INR 37 additionally per patient for BPaLM than the mixed SoC to gain one QALY. Interpretation & conclusions: Our findings indicate that BPaL based regimens are likely to be cost-saving and more effective than the current mixed SoC in a range of settings. Countries should consider programmatic uptake of BPaL based regimens to treat MDR/RR-TB.


  • Open Access

    Economic Burden of TB Deaths in India (2021): A Retrospective Cross-sectional Study

    by Karikalan Nagarajan, Malaisamy Muniyandi, Venkateshprabhu Janagaraj, Karthick Chelvanayagam, Stephen Arangba, Senthil Sellappan, Mahalingam Vasantha

    Background: India accounts for 26% of global tuberculosis (TB) deaths. Evidence of economic losses due to TB deaths can influence policy decisions and optimising resource allocations. In this study, we estimated the economic burden of TB deaths in terms of GDP across Indian states, regions and different demographic groups. Methodology: In this modelling study, using Human Capital Approach (HCA), we estimated the non-health GDP losses due to TB deaths in India for 2021 at sub-national level. The total monetary value for the years of life lost (TMVYLL) due to TB deaths was calculated. To check the uncertainty in the economic losses, sensitivity analysis was conducted using different discount rates of 3%, 5% and 10%. Results: In 2021, 0.393 million TB deaths occurred in India, which would reduce the non-health GDP by US$9.1 billion. Nearly 33.5%, 25.6%, 18.5% and 9.3% of that economic loss would come from North, West, South and North East states of India respectively. On an average, each TB death resulted in non-health GDP loss of US$23161. The economic burden was highest among younger males (20.5%) followed by males aged >75 years (17.3%). The economic cost was minimal among adolescents and young males accounting only for 3.4%. Conclusion: Our HCA driven estimates underscore a high economic burden of TB in the Northern and Western Zones of India, particularly among youth and males. These findings underscore the urgent need for concerted multi-sectoral efforts, sustained investments and strategies to reduce TB deaths and mitigate the resulting economic losses.


  • Open Access

    Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India

    by Malaisamy Muniyandi, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal, Jyoti Jaju, Chandrasekaran Padmapriyadarsini

    Background: Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6–9 months) to treat drug-resistant tuberculosis (DR-TB) compared to the current standard of care (SoC) 9- to 11-month regimen. Methods: Cost-effectiveness of various short-course DR-TB treatment regimens, namely BEAT, BPaL, BPaLM, BPaLC, mBPaL1, mBPaL2, and mBPaL3, was compared to the current SoC in India. Decision tree model was used from a health system perspective. The information on various costs – such as preinvestigations, regimens, adverse drug reactions (ADRs) management, inpatient treatment – and on effect – such as clinical outcomes and ADRs – was collected from different published sources. It estimated costs, quality-adjusted life years, and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to validate outcomes against the willingness-to-pay threshold. Results: When all the short-course regimens were compared with the current SoC regimen, the ICERs were ₹5,385, ₹2,014, ₹2,008, ₹2,435, ₹1,462, ₹1,159, and ₹1,895 for BEAT, BPaL, BPaLM, BPaLC, mBPaL1, mBPaL2, and mBPaL3, respectively. Among the short-course regimens, mBPaL2 is the dominant strategy, and mBPaL1 has extended dominance. For all Bedaquiline-containing regimens, the cost of the drug is a crucial factor in determining cost effectiveness. The cost-effectiveness acceptability curve showed that all shorter regimens were 100 percent cost-effective. Conclusion: The implementation of Bedaquiline-based regimen to treat DR-TB has become more effective, shorter in duration, and less burdensome to the health system.


  • Corrigendum to “Significant reduction of seizure frequency in patients with drug-resistant epilepsy by vagus nerve stimulation: Systematic review and meta-analysis” [Epilepsy Res. 210 (2025) 107510]

    by Malaisamy Muniyandi, Karthick Chelvanayagam, Sahil Abdul Salam, Sathishkumar Vadamalai, Kavitha Rajsekar, Rajeswari Ramachandran

  • Open Access

    Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu

    by Vasantha Mahalingam, Ramesh Kumar Santhanakrishnan, Muniyandi Malaisamy, Karthick Chelvanayagam, Kavi Mathiyazhagan, Adhin Bhaskar, Karikalan Nagarajan, Jerard Maria Selvam, Surendran Veeraiah, Kavitha Rajsekar, et al.

    Background: Smoking is a major public health concern in Tamil Nadu, as it is in many parts of the world. It is a leading cause of preventable diseases and deaths, with a significant economic burden on healthcare systems and society as a whole. Recognizing the need to address this issue, the implementation of smoking cessation strategies at primary health care (PHC) settings has gained attention. Conducting a cost-effectiveness analysis in this context can help policymakers and healthcare providers make informed decisions about the allocation of resources for such interventions. Objectives: To compare the cost-effectiveness of the smoking cessation of proposed strategies (PSs), PS1: enhanced counselling (EC) + nicotine replacement therapy (NRT) + bupropion tablet; PS2: behavioural intervention (BI) + NRT + promotion of bupropion sustained release (SR); PS3: EC + NRT + promotion of bupropion SR with the current strategy (BI +NRT+ Bupropion) in a population of smokers aged ≥15 years attending the PHC in Tamil Nadu. Methods: In this hypothetical cohort of 100,000 individuals using the decision tree analysis, a cost-effectiveness assessment was conducted for both proposed and existing strategies. The results were evaluated in terms of incremental cost-effectiveness ratios (ICERs) per person quitting smoking. To assess the robustness of the findings, one-way sensitivity analysis and probabilistic sensitivity analysis were performed which aims to explore and address the uncertainties associated with the outcomes. Results: The cost of the current strategy (CS) was higher (₹359 or $4.28 million) when compared with PS1 (₹327 or $3.90 million) and PS3 (₹327 or $3.90 million) strategies. The PS2 with BI + bupropion SR + NRT was found to be more cost (₹2,720,571 or $ 32,414.76) as compared to current strategy. ICER values indicates that compared to the current strategy, the PS1 and PS3 were found to be cost-saving, whereas the PS2 was found to be cost-effective. The cost-effectiveness acceptability curve demonstrated that the PS1 and PS3 indicates 100% probability of the intervention being cost-saving. After excluding dominated interventions (PS2 and CS), the remaining strategies (PS1 and PS3) were compared. The PS3, with an incremental cost of ₹462,497 ($5,510) for 131 additional quitters, resulted in an ICER of ₹3,531 ($42) per quitter, making it a cost-effective option compared to PS1. Conclusion: Our study findings indicate that the need for healthcare providers and policymakers to implement PS3 with EC, NRT, Bupropion SR, as which was found to be cost-saving compared to current practices.


  • Significant reduction of seizure frequency in patients with drug-resistant epilepsy by vagus nerve stimulation: Systematic review and meta-analysis

    by Malaisamy Muniyandi, Karthick Chelvanayagam, Sahil Abdul Salam, Sathishkumar Vadamalai, Kavitha Rajsekar, Rajeswari Ramachandran